Biomotion Sciences (SLXN)
NASDAQ:SLXN
US Market
Holding SLXN?
Track your performance easily

Biomotion Sciences (SLXN) Income Statement

18 Followers

Biomotion Sciences Income Statement

Last quarter (Q ), Biomotion Sciences's total revenue was $―, a decrease of ― from the same quarter last year. In Q, Biomotion Sciences's net income was $1.37M. See Biomotion Sciences’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20
Total Revenue
--$ 0.00$ 0.00$ 0.00
Cost of Revenue
-----
Gross Profit
-----
Operating Expense
$ 725.11K$ 4.68M$ 1.23M$ 943.93K$ 195.86K
Operating Income
$ -725.11K$ -4.68M$ -1.23M$ -943.93K$ -195.86K
Net Non Operating Interest Income Expense
$ 1.51M$ 144.00K$ 1.69M$ 6.37K$ 0.00
Other Income Expense
$ -836.00$ 86.00K$ 130.70K$ 182.34K-
Pretax Income
$ 2.20M$ -5.08M$ 584.02K$ -755.22K$ -195.86K
Tax Provision
$ -5.00K$ 32.00K---
Earnings From Equity Interest Net Of Tax
-----
Net Income Common Stockholders
$ 2.16M$ -4.94M$ 584.02K$ -755.22K$ -195.86K
Basic EPS
$ 5.66$ 19.57$ 0.16$ -0.23$ -0.07
Diluted EPS
$ 5.49$ 19.57$ 0.04$ -0.23$ -0.07
Basic Average Shares
$ 7.76M$ 252.46K$ 3.56M$ 3.30M$ 2.88M
Diluted Average Shares
$ 30.76M$ 252.46K$ 15.05M$ 13.18M$ 2.88M
Dividend Per Share
-----
Total Operating Income As Reported
-----
Reported Normalized Basic E P S
-----
Reported Normalized Diluted E P S
-----
Rent Expense Supplemental
-----
Total Expenses
$ 725.11K$ 4.68M$ 1.23M$ 943.93K$ 195.86K
Net Income From Continuing And Discontinued Operation
$ 2.16M$ -4.94M$ 584.02K$ -755.22K$ -195.86K
Normalized Income
$ 2.20M$ -3.73M$ 505.60K$ -937.56K$ -195.86K
Interest Expense
-----
EBIT
$ 692.89K$ -5.22M$ -1.23M$ -943.93K$ -195.86K
EBITDA
$ 700.89K$ -5.18M$ -1.23M$ -943.93K$ -195.86K
Currency in USD

Biomotion Sciences Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis